UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of September, 2013
Commission File Number:
000-51310
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
85 Medinat Hayehudim St., Herzliya
Pituach, PO Box 4033,
____________
Herzliya 4614001, Israel
____________
(Address of principal
executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-
N/A
Incorporation by Reference: This Form 6-K of XTL Biopharmaceuticals
Ltd. dated September 11, 2013 is hereby incorporated by reference into the registration statements on Form F-3 (File No. 333-141529,
File No. 333-147024 and File No. 333-153055) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
March 23, 2007, October 30, 2007 and August 15, 2008, respectively, and the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission on
December 14, 2007, January 18, 2008, and October 28, 2008, respectively.
XTL
Biopharmaceuticals Ltd. (hereinafter
“
the Company
”
)
hereby announces that today it received a notification from Mr. David Grossman, the Company’s Chief Executive Officer (
“
CEO
”
)
to the Company’s Board of Directors, of his wish to cease his service as the Company's CEO. Therefore, the Company's Board
of Directors has today approved the nomination and compensation of Mr. Josh Levine as CEO. Mr. Grossman will cease his role as
CEO upon the effective date of Mr. Levine’s assumption of the office. The Company shall disclose the exact timing of the
effective date once such information becomes available.
Mr. Levine's terms as CEO are subject to
approval at a Company shareholder meeting. It is the Company's intention to file an immediate report in short order to announce
convening a shareholder meeting to determine the terms of Mr. Levine’s employment as CEO of the Company.
About XTL Biopharmaceuticals Ltd. (“XTL”)
XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of clinical unmet needs. XTL is focused on late stage clinical development of drugs for the treatment
of multiple myeloma, schizophrenia, and hepatitis C.
XTL’s
lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood cancer, was granted an orphan drug designation from the
FDA. rHuEPO has been approved for marketing by the FDA and has for many years been sold for billions of dollars across the world
for the treatment of severe anemia.
XTL
holds more than 44.9% in Proteologics Ltd. (TASE: PRTL), and controls InterCure Ltd. (TASE: INCR), a company which has disrupted
the $42 billion hypertension industry with the world's first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (www.resperate.com).
XTL
is a public company traded on the NASDAQ Stock Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are
included in the following indices: Tel-Aviv MidCap-50, Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.
Contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080, Email:
ir@xtlbio.com
,
www.xtlbio.com
Contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080, Email: ir@xtlbio.com
Cautionary Statement
Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: September 11, 2013
|
By:
|
/s/ David Grossman
|
|
|
|
David Grossman
|
|
|
|
Chief Executive Officer
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Oct 2024 to Nov 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Nov 2023 to Nov 2024
